Sign in

CIK 0001549595

  • Large accelerated filer

Nurix Therapeutics, Inc.

Sign in to watch
Ticker
NRIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Nov 30
Incorporated
DE
Entity type
Operating
EIN
270838048
Phone
+1 415-660-5320
Business address
1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
Former names
Nurix, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$1,712,859
in 10 filings, $1.0M under 10b5-1 plans

Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 50 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-06-05 Ring Christine Chief Legal Officer Option exercise 10b5-1 +400 $1.86 $744 20,238
2024-06-05 Ring Christine Chief Legal Officer Sale 10b5-1 −400 $17.00 $7K 19,838
2024-06-05 Ring Christine Chief Legal Officer Option exercise · Employee Stock Option (right to buy) 10b5-1 −400 98,070
2024-06-03 Ring Christine Chief Legal Officer Option exercise 10b5-1 +1,596 $1.86 $3K 21,434
2024-06-03 Ring Christine Chief Legal Officer Sale 10b5-1 −1,596 $17.01 $27K 19,838
2024-06-03 Ring Christine Chief Legal Officer Option exercise · Employee Stock Option (right to buy) 10b5-1 −1,596 98,470
2024-05-20 Silva Paul M Director Grant or award · Director Stock Option (right to buy) +25,000 25,000
2024-05-20 Kunkel Lori Anne Director Grant or award · Director Stock Option (right to buy) +25,000 25,000
2024-05-20 GREGORY JULIA P Director Grant or award · Director Stock Option (right to buy) +25,000 25,000
2024-05-20 Lacey David L. Director Grant or award · Director Stock Option (right to buy) +25,000 25,000
2024-05-20 Reinsdorf Judith A Director Grant or award · Director Stock Option (right to buy) +25,000 25,000
2024-05-20 Saltzman Edward C Director Grant or award · Director Stock Option (right to buy) +25,000 25,000
2024-05-02 van Houte Hans Chief Financial Officer Sale 10b5-1 −3,499 $12.83 $45K 68,333
2024-04-30 van Houte Hans Chief Financial Officer Option exercise +2,886 71,219
2024-04-30 van Houte Hans Chief Financial Officer Option exercise +2,000 73,219
2024-04-30 van Houte Hans Chief Financial Officer Sale −1,387 $12.04 $17K 71,832
2024-04-30 van Houte Hans Chief Financial Officer Option exercise · Restricted Stock Units −2,886 20,203
2024-04-30 van Houte Hans Chief Financial Officer Option exercise · Restricted Stock Units −2,000 16,000
2024-04-30 Hansen Gwenn Chief Scientific Officer Option exercise +3,206 39,608
2024-04-30 Hansen Gwenn Chief Scientific Officer Option exercise +2,000 41,608

Page 21 of 32 · 632 trades